Cargando…

Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line

Exploring mechanisms of drug resistance to targeted small molecule drugs is critical for an extended clinical benefit in the treatment of non-small cell lung cancer (NSCLC) patients carrying activating epidermal growth factor receptor (EGFR) mutations. Here, we identified constitutive cell prolifera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saafan, Hisham, Alahdab, Ahmad, Michelet, Robin, Gohlke, Linus, Ziemann, Janine, Holdenrieder, Stefan, McLaughlin, Katie-May, Wass, Mark N., Cinatl, Jindrich, Michaelis, Martin, Kloft, Charlotte, Ritter, Christoph A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103245/ https://www.ncbi.nlm.nih.gov/pubmed/33804833 http://dx.doi.org/10.3390/cells10040716

Ejemplares similares

Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC
por: Gohlke, Linus, et al.
Publicado: (2023)

Drug-adapted cancer cell lines as preclinical models of acquired resistance
por: Michaelis, Martin, et al.
Publicado: (2019)

COVID-19-Related Coagulopathy—Is Transferrin a Missing Link?
por: McLaughlin, Katie-May, et al.
Publicado: (2020)

Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G(2)/M cell cycle arrest
por: Sarin, Navin, et al.
Publicado: (2017)

SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment
por: Bojkova, Denisa, et al.
Publicado: (2022)

Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates
por: Bojkova, Denisa, et al.
Publicado: (2022)

Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin
por: Dilruba, Shahana, et al.
Publicado: (2020)

Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A
por: Yu, H-C, et al.
Publicado: (2014)

SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine
por: Rothenburger, Tamara, et al.
Publicado: (2020)

Differentially conserved amino acid positions may reflect differences in SARS-CoV-2 and SARS-CoV behaviour
por: Bojkova, Denisa, et al.
Publicado: (2021)

Incorporation of doxorubicin in different polymer nanoparticles and their anticancer activity
por: Pieper, Sebastian, et al.
Publicado: (2019)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells
por: Onafuye, Hannah, et al.
Publicado: (2019)

Omeprazole Increases the Efficacy of Acyclovir Against Herpes Simplex Virus Type 1 and 2
por: Michaelis, Martin, et al.
Publicado: (2019)

A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis
por: McLaughlin, Katie-May, et al.
Publicado: (2021)

Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants
por: Bojkova, Denisa, et al.
Publicado: (2022)

Aprotinin Inhibits SARS-CoV-2 Replication
por: Bojkova, Denisa, et al.
Publicado: (2020)

Towards image-based cancer cell lines authentication using deep neural networks
por: Mzurikwao, Deogratias, et al.
Publicado: (2020)

Effects of flavonoid-induced oxidative stress on anti-H5N1 influenza a virus activity exerted by baicalein and biochanin A
por: Michaelis, Martin, et al.
Publicado: (2014)

Investigation of the influence of EPs(®) 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses
por: Michaelis, Martin, et al.
Publicado: (2011)

YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting
por: Michaelis, Martin, et al.
Publicado: (2020)

Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines
por: Michaelis, Martin, et al.
Publicado: (2020)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
por: Nishio, Kazuto, et al.
Publicado: (2021)

Erlotinib and Concurrent Chemoradiation in Pretreated NSCLC Patients: Radiobiological Basis and Clinical Results
por: Ramella, Sara, et al.
Publicado: (2013)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport
por: Michaelis, Martin, et al.
Publicado: (2016)

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib
por: Michaelis, Martin, et al.
Publicado: (2015)

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

A microRNA signature of response to erlotinib is descriptive of TGFβ behaviour in NSCLC
por: Krentz Gober, Madeline, et al.
Publicado: (2017)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

Development of antiviral therapy for severe acute respiratory syndrome
por: Cinatl, Jindrich, et al.
Publicado: (2005)

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance
por: Voges, Yvonne, et al.
Publicado: (2016)

Inhibition of apoptosis prevents West Nile virus induced cell death
por: Kleinschmidt, Malte C, et al.
Publicado: (2007)

Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status
por: Michaelis, Martin, et al.
Publicado: (2015)

Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines
por: Morgenstern, Birgit, et al.
Publicado: (2005)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
por: Cavazzoni, Andrea, et al.
Publicado: (2012)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

Miyabeacin: A new cyclodimer presents a potential role for willow in cancer therapy
por: Ward, Jane L., et al.
Publicado: (2020)

VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
por: Kuiper, J L, et al.
Publicado: (2012)

Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
por: Lee, Siow Ming, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_97h209p759gei2dnplmt9clkej